Biologic discontinuation studies: A systematic review of methods

Annals of the Rheumatic Diseases

Volumn 73, Issue 3, 2014, Pages 595-599

  Yoshida, Kazuki ^a,b   Sung, Yoon Kyoung ^a,c   Kavanaugh, Arthur ^d   Bae, Sang Cheol ^c   Weinblatt, Michael E ^a   Kishimoto, Mitsumasa ^e   Matsui, Kazuo ^b   Tohma, Shigeto ^f   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KAMEDA MEDICAL CENTER   (Japan)

^c Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^f SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGIC DMARDS; DISCONTINUATION; REMISSION; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; REMISSION INDUCTION; RESEARCH DESIGN; TERMINOLOGY AS TOPIC; TREATMENT FAILURE; WITHHOLDING TREATMENT;

EID: 84893795344     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203302     Document Type: Article

References (16)

1. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
2. Chatzidionysiou K, Turesson C, Teleman A, et al. A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission [abstract]. Arthritis Rheum 2012;64(Suppl 10):S336.
3. Harigai M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012;22:814-22.
4. Smolen JS, Emery P, Ferraccioli G, et al. Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the CERTAIN study. Ann Rheum Dis 2012;71(Suppl 3):361.
5. Van Vollenhoven R, Østergaard M, Leirisalo-Repo M, et al. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial [abstract]. Arthritis Rheum 2012;64:4171.
6. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72: 844-50.
7. Tanaka Y, Hirata S, Fukuyo S, et al. Discontinuation of adalimumab without functional and radiographic damage progression after achieving sustained remission in patients with rheumatoid arthritis (the HONOR study): 1-year results [abstract]. Arthritis Rheum 2012;64(Suppl 10):345.
8. Van der Maas A, Kievit W, Van den Bemt BJF, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012;71:1849-54.
9. Kavanaugh A, Emery P, Fleischmann RM, et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2012;51(Suppl 3):iii27.
10. Van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
11. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
12. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5.
13. Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008; 18:460-4.
14. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35. (Pubitemid 40129229)
15. Bruynesteyn K, Van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913-20. (Pubitemid 34303802)
16. Bartlett SJ, Hewlett S, Bingham CO III, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855-60.